Business Wire

CA-SD-ASSOCIATION

19.5.2020 14:02:05 CEST | Business Wire | Press release

Share
SD Express Delivers New Gigabyte Speeds for SD Memory Cards

The SD Association announced today the SD 8.0 Specification for SD Express memory cards receives even faster transfer speeds by using the popular PCI Express® (PCIe® ) 4.0 specification delivering a maximum of nearly 4 gigabytes per second (GB/s) data transfer rate. These full sized cards continue to use the NVMe Express™ (NVMe™) upper layer protocol enabling advanced memory access mechanism. As always SD Express memory cards using SD 8.0 specification maintain backward compatibility.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200519005027/en/

“SD Express’ use of even faster PCIe and NVMe architectures to deliver faster transfer speeds creates more opportunities for devices to use SD memory cards,” said Mats Larsson, Senior Market Analyst at Futuresource. “This combination of trusted and well-known technologies makes it easier for future product designs to leverage the benefits of removable storage in new ways.”

SD Express gigabyte speeds bring new storage opportunities for devices with demanding performance levels, across a variety of industries. The cards can move large amounts of data generated by data-intense wireless or wired communication, super-slow motion video, RAW continuous burst mode and 8K video capture and playback, 360 degree cameras/videos, speed hungry applications running on cards and mobile computing devices, ever evolving gaming systems, multi-channel IoT devices and automotive to name a few. SD Express will be offered on SDHC, SDXC and SDUC memory cards.

“By dramatically increasing the speeds for SD Express we’re giving device manufacturers and system developers more storage choices,” said Hiroyuki Sakamoto, SDA president. “SD 8.0 may open even more opportunities for extra high performance solutions using removable memory cards.”

“PCI-SIG® is pleased to see that SDA is continuing to adopt even faster PCIe technology configurations using PCIe 4.0 interface and dual lanes for one of the top leading removable memory cards – SD,” said Al Yanes, PCI-SIG president and chairman. “PCIe specification conformance tests are available today by major test vendors, offering a significant advantage for any new PCIe technology adopter.”

“NVMe is the industry-recognized performance SSD interface from the client to the datacenter, shipping in millions of units,” said Amber Huffman, NVM Express™ Inc. president. “Consumers will benefit by SD Association continuing the adoption of the NVMe base specification for their latest SD Express cards.”

SD Express uses the well-known PCIe 4.0 specification and the latest NVMe specification (up to version 1.4) defined by PCI-SIG and NVM Express, respectively. SD 8.0 specification provides two transfer speed options for SD Express memory cards. The two transfer speeds are accomplished by supporting either PCIe 3.0 x2 or PCIe 4.0 x1 architectures with up to ~2GB/s and with PCIe 4.0 x2 technology with up to 4GB/s. SD Express cards offering PCIe 4.0 x1 architecture use the same form factor as defined for SD 7.0 specification cards with a second row of pins to deliver transfer speeds up to 2 GB/s. SD Express cards supporting dual PCIe lanes (PCIe 3.0 x2 or PCIe 4.0 x2 technologies) have three rows of pins.

The SDA makes adoption of SD Express easy allowing companies to use existing test equipment and saving in product development costs. The SD 8.0 specification continues giving system developers access to PCIe and NVMe technologies, such as Bus Mastering, Multi Queue (without locking mechanism) and Host Memory Buffer.

Two revised white papers, “SD Express Cards with PCIe and NVMe Interfaces ,” and “SD Express and microSD Express Memory Cards: The Best Choice for Your Future Product Designs ” provide an in-depth look at the opportunities created by SD Express. More information is available on our website .

Visit the SDA Virtual Tradeshow to learn more about SD Express solutions offered by our members.

SD Association

The SD Association is a global ecosystem of nearly 900 technology companies charged with setting interoperable SD standards. The Association encourages the development of consumer electronic, wireless communication, digital imaging and networking products that utilize market-leading SD technology. The SD standard is the number one choice for consumers and has earned more than 80 percent of the memory card market with its reliable interoperability and its easy-to-use format. Today, smart phones, tablets, drones, IoT devices, HDTVs, audio players, automotive systems, computers, digital cameras and digital video cameras feature SD interoperability. For more information about SDA or to join, please visit the Association’s website, https://www.sdcard.org .

SD Logos are trademarks licensed by SD-3C LLC.

PCI-SIG

PCI-SIG is the consortium that owns and manages PCI specifications as open industry standards. The organization defines industry standard I/O (input/output) specifications consistent with the needs of its members. Currently, PCI-SIG is comprised of nearly 800 industry-leading member companies. To learn more about PCI-SIG, and for a list of the Board of Directors, visit www.pcisig.com . PCI Express® is a registered trademark of PCI-SIG.

About NVM Express, Inc.

With more than 100 members, NVM Express is a non-profit organization focused on enabling broad ecosystem adoption of high performance and low latency non-volatile memory (NVM) storage through a standards-based approach. The organization offers an open collection of NVM Express (NVMe™) specifications and information to fully expose the benefits of non-volatile memory in all types of computing environments from mobile to data center. NVMe-based specifications are designed from the ground up to deliver high bandwidth and low latency storage access for current and future NVM technologies. For more information, visit http://www.nvmexpress.org .

PCIe® - PCI Express, is a standard developed by PCI-SIG® and PCIe® is a trademark owned by PCI-SIG.

NVMe™ - NVM ExpressTM , is a standard developed by NVM Express Inc. and NVMe™ is a trademark owned by NVM Express Inc.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Andersen Consulting tilføjer House of Code for at styrke teknologi- og dataløsninger26.6.2026 20:01:00 CEST | Pressemeddelelse

Andersen Consulting forstærker sine kompetencer inden for teknologisk transformation gennem en samarbejdsaftale med House of Code, en global virksomhed med hovedkvarter i USA, der specialiserer sig i datadrevne platforme, automatisering og agentbaserede ai-løsninger. House of Code blev stiftet i 2001 og udvikler softwareløsninger samt yder rådgivning til energihandels- og finanssektoren med kunder, der spænder over hedgefonde, kapitalfonde og forsyningsvirksomheder. Virksomheden besidder dyb ekspertise inden for energihandel og risikostyring og hjælper organisationer med systemimplementering, forretningstransformation, dataautomatisering og ai-underbygget modernisering af arbejdsgange. Deres proprietære platform, Enterprise Platform for Integrated Compliance (EPIC), skaber en mere effektiv datastyring, automatiserer rapporteringsprocesser, forbedrer den driftsmæssige gennemsigtighed på tværs af virksomhedssystemer og skaber et fundament for opbygning af intelligente, agentbaserede arbe

Capco Recognized by OpenAI for Innovation and Responsible AI Leadership26.6.2026 20:00:00 CEST | Press release

Receives AI Governance & Risk Excellence Award at OpenAI Partner SummitCapco’s UK AI Lab wins OpenAI Codex Hackathon Global management and technology consultancy Capco, a Wipro company,has been recognized by OpenAI for both AI innovation and responsible AI leadership. Capco received the AI Governance & Risk Excellence Award at the recent OpenAI Partner Summit 2026 in San Francisco, highlighting Capco’s ability to deliver enterprise-grade AI outcomes in highly regulated environments. The award recognizes Capco’s expert advantage when helping financial services and energy organizations to scale AI with confidence, balancing innovation with strong governance to reduce risk, strengthen compliance and improve customer outcomes. This award follows Capco winning the OpenAI Codex Hackathon, where its UK AI Lab competed against more than 30 teams and over 100 participants from across the OpenAI partner ecosystem. Capco's winning entry Sentra – a consulting-led, AI-powered retail banking solutio

Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release

If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids

Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release

Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use

DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release

-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye